| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| GADICKE ANSBERT | Former 10% Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke | 15 May 2025 | 0001134655 |
| MPM BioImpact LLC | Former 10% Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund L.P | 15 May 2025 | 0001687078 |
| Oncology Impact Fund (Cayman) Management L.P. | Former 10% Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P. | 15 May 2025 | 0001721036 |
| UBS Oncology Impact Fund L.P. | Former 10% Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC | 15 May 2025 | 0001691428 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Common Stock | Sale | -$8.32M | -1.03M | -23.01% | $8.06 | 3.45M | 13 May 2025 | See Footnote | F1, F2, F3, F4 |
Ansbert Gadicke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. |
| F2 | MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |